Drug intelligence / Profile preview

CannabiNext

Development stage: Preclinical
Lead developer: Imuneks Farma
Modality: Small Molecules
Administration: Oral

Overview

CannabiNext is a next-generation water-soluble cannabinoid formulation developed by İmuneks Farma. It is designed to overcome the inherent challenges of poor aqueous solubility and low bioavailability associated with lipophilic cannabinoid compounds. By utilizing advanced formulation technology, CannabiNext aims to improve the delivery and absorption of cannabinoids for use in nutraceutical and dietary supplement applications. While the specific cannabinoid profile and clinical indications are not publicly disclosed, the product is part of the company's research into optimized delivery systems for natural bioactive substances.

Brand names: CannabiNext
Other names: CannabiNext Next Generation Water Soluble CannabinoidsCannabiNext (water soluble cannabinoids)

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on CannabiNext.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CannabiNext.

Explore the full profile